Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00099242 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,040
- Enrollment target
NCT00099242: Completed Phase 3 study, sponsored by Novartis Pharmaceuticals.
NCT00099242 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 1,040 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00099242, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,040 participants
- Enrollment target
Study Summary
The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
Interventions
- DRUG rivastigmine transdermal patch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,040 participants |
| Start Date | 2003-11 |
| Est. Completion | 2006-01 |
| Phase | Phase 3 |
What the finished NCT00099242 record still lists
NCT00099242 is an interventional study that assigns participants to a tested intervention. Its 1,040 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% higher).
The record links to 0 conditions, and to 1 intervention - of which rivastigmine transdermal patch is the first listed.
NCT00099242 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00099242 about?
NCT00099242 is a clinical study titled "Efficacy and Safety of the Rivastigmine Transdermal Patch in Patients With Probable Alzheimer's Disease". The goal of this research study is to evaluate the safety and efficacy of the rivastigmine transdermal patch in patients with probable Alzheimer's Disease.
What is the current status of trial NCT00099242?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,040 participants. The study started on 2003-11. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00099242?
The interventions under investigation include: rivastigmine transdermal patch (DRUG).
Who is sponsoring clinical trial NCT00099242?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00099242's enrollment target sits among peer trials
1,040 285th of 2000 higher than 1,714 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05219110 · 1,040 participants · NA
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
- NCT06564948 · 1,040 participants · NA
Treatment for Individuals Interacting with the Criminal Justice System
- NCT06661720 · 1,040 participants · Phase 3
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
- NCT04685616 · 1,042 participants · Phase 3
Brentuximab Vedotin in Early Stage Hodgkin Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia